Clinical trial Allo-Shrink
An open-label, Phase I study to assess the safety of multiple doses of CYAD-101, administered after standard FOLFOX chemotherapy in patients with unresectable metastatic colorectal cancer
| Cancers | |
|---|---|
| Organ | Colon |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | Celyad |
| EudraCT Identifier | 2018-000927-14 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03692429 |
| Inclusion criteria | Unresacable metastasis. RECIST v1.1. Can receive FOLFOX |
| Last update |